FLUTEMETAMOL F-18

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H11FN2OS
Molecular Weight	273.316
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC1=CC=C(C=C1[18F])C2=NC3=C(S2)C=C(O)C=C3

InChI

InChIKey=VVECGOCJFKTUAX-HUYCHCPVSA-N

InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3/i15-1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203137s005lbl.pdf

Flutemetamol F 18 is a radioactive molecular agent that is intended for use with PET imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia. Flutemetamol F 18 consists of flutemetamol, a thioflavin derivative of Pittsburgh compound B (PiB) labeled with the radioisotope fluorine F18 and it selectively binds to cerebral fibrillar beta-amyloid, a peptide involved in Alzheimer's disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Amyloid beta A4 protein 4 Target ID: P05067\|\|\|Q13764\|\|\|Q8WZ99 Gene ID: 351.0 Gene Symbol: APP Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=22011144	Binding Agent 1064		6.7 nM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 272 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203137s005lbl.pdf	Diagnostic		Approved 8429	VIZAMYL Approved Use Vizamyl is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. Launch Date 2013

Doses

Dose	Population	Adverse events
185 MBq 1 times / day single, intravenous Recommended Dose: 185 MBq, 1 times / day Route: intravenous Route: single Dose: 185 MBq, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf	unknown, 62 (18-93) n = 761 Health Status: unknown Age Group: 62 (18-93) Sex: M+F Population Size: 761 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf	Other AEs: Hypersensitivity reaction... Other AEs: Hypersensitivity reaction (grade 3-4, 1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf
355.9 MBq 1 times / day single, intravenous Recommended Dose: 355.9 MBq, 1 times / day Route: intravenous Route: single Dose: 355.9 MBq, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf	unhealthy, 72 n = 1 Health Status: unhealthy Condition: Parkinson's disease Age Group: 72 Sex: F Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf	Disc. AE: Anaemia... AEs leading to discontinuation/dose reduction: Anaemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf

AEs

AE	Significance	Dose	Population
Hypersensitivity reaction	grade 3-4, 1%	185 MBq 1 times / day single, intravenous Recommended Dose: 185 MBq, 1 times / day Route: intravenous Route: single Dose: 185 MBq, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf	unknown, 62 (18-93) n = 761 Health Status: unknown Age Group: 62 (18-93) Sex: M+F Population Size: 761 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf
Anaemia	Disc. AE	355.9 MBq 1 times / day single, intravenous Recommended Dose: 355.9 MBq, 1 times / day Route: intravenous Route: single Dose: 355.9 MBq, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf	unhealthy, 72 n = 1 Health Status: unhealthy Condition: Parkinson's disease Age Group: 72 Sex: F Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 270

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.ema.europa.eu/en/documents/assessment-report/vizamyl-epar-public-assessment-report_en.pdf#page=23 Page: 23.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000PharmR.pdf#page=45 Page: 45.0

PubMed

Title	Date	PubMed
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).	2011 Dec 8	22011144
Clinical amyloid imaging in Alzheimer's disease.	2011 Jul	21683932
Alzheimer's imaging agents struggle to find a market outside trials.	2013 Dec	24309640

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose for Vizamyl is 185 megabecquerels (MBq) [5 millicuries (mCi)] in a maximum dose volume of 10 mL, administered as a single intravenous bolus within 40 seconds. The maximum mass dose is 20 micrograms. Follow the injection with an intravenous flush of 5 to 15 mL of 0.9% sterile sodium chloride injection.

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Name

Type

Language

FLUTEMETAMOL F-18

Common Name

English

FLUTEMETAMOL ((SUP18)F)

Common Name

English

(18F)FLUTEMETAMOL [MI]

Common Name

English

FLUTEMETAMOL (18F)

Official Name

English

VIZAMYL

Brand Name

English

flutemetamol (¹⁸F) [INN]

Common Name

English

2-(3-(SUP 18)F)FLUORO-4-(METHYLAMINO)PHENYL)-1,3-BENZOTHIAZOL-6-OL

Common Name

English

(18F)AH110690

Code

English

FLUTEMETAMOL F-18 [ORANGE BOOK]

Common Name

English

FLUTEMETAMOL F 18 [USAN]

Common Name

English

FLUTEMETAMOL F 18

Official Name

English

Flutemetamol (18f) [WHO-DD]

Common Name

English

AH-110690 F-18

Code

English

Classification Tree Code System Code

NDF-RT

N0000177914